Investing Ideas
/
Taiwanese Pharmaceuticals & Biotech Undervalued based on future growth

Taiwanese Pharmaceuticals & Biotech Undervalued based on future growth

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

1 new

Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)

1 companies

PharmaEssentia

Market Cap: NT$179.3b

A biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally.

New

6446

NT$538.00

5.9%

11.6%